rethinkTHC Search
Menu
Study breakdown

Could the Endocannabinoid System Help Treat Malignant Hyperthermia?

ReviewPreliminary evidence
The takeaway

A review proposes that cannabinoid receptor activation could counteract the dangerous calcium overload in malignant hyperthermia by reducing muscle calcium release through CB1-mediated inhibition of ryanodine receptor phosphorylation.

Anesthesiologists; endocannabinoid researchers; pharmacologists studying calcium signaling

CB1 activation inhibits the same PKA/RYR1 pathway that drives malignant hyperthermia

What the researchers found

CB1 receptor activation inhibits PKA-mediated phosphorylation of RYR1 and L-type calcium channels, potentially reducing the excessive calcium release that causes malignant hyperthermia. Preclinical studies show CB1 agonism lowers body temperature and reduces cardiovascular stress.

Why it matters

Malignant hyperthermia is life-threatening and has only one primary treatment (dantrolene), which has significant side effects. If cannabinoids can modulate the same calcium pathways, they could offer an adjunctive therapy.

The numbers in context

CB1 activation inhibits PKA-mediated phosphorylation of RYR1 and L-type calcium channels. TRPV1 antagonism or desensitization reduces sarcoplasmic reticulum calcium release.

How the study worked

Narrative review synthesizing molecular evidence linking endocannabinoid signaling to calcium homeostasis in skeletal muscle and its potential relevance to malignant hyperthermia.

What this study cannot tell us

Theoretical review based on indirect molecular evidence. No studies have tested cannabinoids specifically in malignant hyperthermia models. The proposed mechanisms need experimental validation in RYR1-mutant models.

How to read the evidence

Theoretical review proposing a novel mechanism; no direct experimental evidence in MH models yet.

When this study was published

2025 review synthesizing current molecular evidence

The bigger picture

This review connects two previously separate fields: anesthesiology/pharmacogenetics and endocannabinoid research. If validated, it could represent an entirely new therapeutic approach for a rare but deadly condition.

Questions still open

  • Would cannabinoids be safe during anesthesia? Could they interfere with the triggering volatile anesthetics? What dose and timing would be needed for a protective effect?

Common questions

What is malignant hyperthermia?
A life-threatening reaction to certain anesthetics that causes uncontrolled muscle contraction, dangerously high body temperature, and metabolic crisis. It is caused by genetic mutations in the ryanodine receptor (RYR1).
Could cannabis use protect against malignant hyperthermia?
This is purely theoretical at this point. The review proposes a molecular rationale but no studies have tested whether cannabinoids would actually prevent or treat MH episodes.

Read the original research

The endocannabinoid system & malignant hyperthermia: From molecular signaling towards clinical implications.

Progress in lipid research, 99, 101342

Citation

Dalle, Simon; Dalle, Sebastiaan. (2025). The endocannabinoid system & malignant hyperthermia: From molecular signaling towards clinical implications.. Progress in lipid research, 99, 101342. https://doi.org/10.1016/j.plipres.2025.101342

Explore the wider topic